[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"wound-care\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:wound-care":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,54,82,116,150,184,203,229,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100651606","effectiveness-and-costs-of-pressure-ulcer-treatment-and-the-quality-of-life-of-patients-with-pressure-ulcers-receiving-home-based-and-institutional-care-100651606",false,"NCT07763106","Effectiveness and Costs of Pressure Ulcer Treatment and the Quality of Life of Patients With Pressure Ulcers Receiving Home-Based and Institutional Care","Comparative Assessment of the Effectiveness and Costs of Pressure Ulcer Treatment and the Quality of Life of Patients With Pressure Ulcers Receiving Home-Based and Institutional Care","Inclusion Criteria:\n\n* Women and men aged 60 to 90 years,\n* stage II-IV pressure ulcers in the lumbar-sacral area of the trunk, pelvic girdle, and lower limbs,\n* high risk of pressure ulcers (above 15 points on the Waterlow scale),\n* daily functional ability below 40 points on the Barthel scale,\n* consent from the patient or legal guardian\u002Fcaregiver to participate in the study.\n\nExclusion Criteria:\n\n* General contraindications (acute inflammatory conditions and febrile illnesses, venous thrombosis, cachexia),\n* pressure ulcers requiring surgical treatment (black necrosis, inflammation of bones and soft tissues),\n* tunneling pressure ulcers showing signs of acute inflammation,\n* pressure ulcers showing signs of infection (causing fever, swelling, pain, and unpleasant odor),\n* pressure ulcers with a surface area of less than 0.5 cm2,\n* pressure ulcers occurring on the lower legs or feet in patients with acute and chronic venous insufficiency and diabetes,\n* multiple pressure ulcers (\\>2),\n* malignant tumors,\n* decompensated diabetes,\n* end-stage chronic heart failure,\n* end-stage renal disease,\n* mental illness.","ALL","60 Years","90 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","A study aimed at comparing the effectiveness of treatment, costs, and quality of life of patients with pressure ulcers in home care and institutional care.\n\nEighty individuals aged 60-90 years with stage II-IV pressure ulcers can participate in the study.\n\nParticipants will be assessed for factors such as health status, independence, mood, and quality of life.\n\nThe study will allow for better tailoring care to patients' needs. Other benefits of participating in the study is that the participants will receive a detailed assessment of their health, nutrition, quality of life, as well as support in managing their pressure ulcers. They will receive regular care and medical evaluations, which may positively impact their health and well-being.\n\nRefusing to participate in this study will not affect the patients treatment in any way.\n\nPlease ask if there is anything that is unclear or if you would like additional information.\n\nTaking part in this study is entirely voluntary.",[27,28,29,30,31,32],"Pressure Ulcer (PU)","Pressure Ulcers, Bedsores, Decubitus Ulcer","Quality of Life","INSTITUTIONAL CARE","Wound Closure","Wound Care",[34,35,36,37,38,39,40],"Pressure Ulcer","Quality of life","Home-Based","Institutional Care","wound care","wound closure","wound treatment","NOT_YET_RECRUITING","2026-08-09",{"date":44,"type":45},"2026-08-13","ACTUAL",{"date":47,"type":21},"2026-09-01",{"date":49,"type":21},"2027-12-31",{"name":51,"class":52},"The Jerzy Kukuczka Academy of Physical Education in Katowice","OTHER",3,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":53},"100646029","safety-study-of-microlyte-dualguard-100646029","NCT07695688","Safety Study of Microlyte DualGuard","Feasibility Clinical Trial to Assess the Safety and Potential Effectiveness of Microlyte® DualGuard Wound Dressing on Surgically Created Partial-thickness Donor Site Wounds on Patients Requiring Split- Thickness Skin Grafting; the SAGGA Trial","SAGGA","Inclusion Criteria:\n\n1. Adult patients where creation of a donor site wound for any indication including chronic wound, burn wound, surgical\u002Ftraumatic wound, and tumor excision is indicated.\n2. Thigh donor site wound (DSW) location.\n3. At least 22 years of age.\n4. Ability to understand and provide a signed and dated informed consent form.\n5. Stated willingness to comply with all study procedures and availability for all visits for the duration of the study.\n6. All female subjects of childbearing potential (not surgically sterile or postmenopausal) and male subjects with female partners of childbearing potential must agree to use effective contraception (such as implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence, vasectomy or vasectomized partner) for the duration of the study (84 days).\n7. Fitzpatrick Skin Type (FST I-VI) assessment and documentation at baseline. Subjects of all FST categories (I-VI) are eligible, and the enrollment strategy will ensure that the full range of FST is represented in the study population (10% minimum enrollment in each FST sub-category).\n\nExclusion Criteria:\n\n1. DSW size of \\> 310 cm2\n2. Calculated glomerular filtration rate (GFR) \\\u003C60 ml\u002Fmin\n3. Hypocalcemia defined as serum corrected calcium of \\\u003C8.0 mg\u002Fdl\n4. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 1.5 times the upper limit of normal (ULN).\n5. Serum Creatinine \\> 2.0 mg\u002FdL.\n6. Pregnant, lactating or nursing women.\n7. Unable to provide consent.\n8. Prior adverse reaction or known sensitivity to silver or gallium.\n9. Enrollment in another interventional trial using a systemic therapeutic within 30 days prior to enrollment for this study.\n10. Presumed impairment of wound healing as with prescription drugs or medical diagnoses that have potential to impair wound healing at the discretion of clinical investigator, e.g., cancer, transplant status, autoimmune disease, severe malnutrition, etc.\n11. Any diagnosis with concern for 30-Day mortality.\n12. Any condition that might impair the evaluation of subject safety or that in the investigator opinion would interfere with study requirements.","22 Years",{"count":64,"type":21},53,[24],"The primary purpose of this research is to evaluate the safety and effectiveness of Microlyte® DualGuard wound dressing in the healing of partial thickness donor site wounds, also known as skin graft donor sites. This research will assess wound healing, the occurrence of infection, allergic reaction, pain, and itching while subjects are in the hospital and after discharge. Subjects will complete clinic visits through 12 weeks. This research will also assess the occurrence of donor site wound infection, pain and itching, and scarring at 12 weeks, assessed by subjects using the Patient and Observer Scar Assessment Scale (POSAS).",[31,32],[69,70,71],"Donor site wound","antimicrobial","wound dressing","2026-07-06",{"date":74,"type":45},"2026-07-10",{"date":76,"type":21},"2026-08-30",{"date":78,"type":21},"2027-08",{"name":80,"class":81},"Imbed Biosciences","INDUSTRY",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":88,"enrollmentInfo":89,"targetDuration":91,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100642258","registry-of-outcomes-of-dezawa-musecells-100642258","NCT07645989","Registry of Outcomes of Dezawa MuseCells®","Inclusion Criteria:\n\n1. Received Dezawa MuseCells® as Part of Routine Clinical Care\n2. Patients ( and\u002For authorized representative) capable of providing informed consent and participating in long-term follow-up.\n3. Willingness to Complete Online Survey Assessments\n4. Participants must have reliable access to email or a mobile device and be willing to complete digital surveys at scheduled intervals over a 5-year period.\n5. Diagnosis of a Condition for Which Dezawa MuseCells® Were Administered Includes, but is not limited to, neurologic, musculoskeletal, cardiovascular, immunologic, and systemic degenerative conditions.\n6. Ability to Communicate in the Registry's Supported Language\n7. Participants must be able to read and respond to registry surveys in the designated study language.\n8. Enrollment Within 12 Months of MuseCell® Administration\n\nExclusion Criteria:\n\n1. Not Receive Dezawa MuseCells®-Individuals who have not been treated with Dezawa MuseCells® or received a counterfeit\u002Fnon-licensed product cannot be included.\n2. Unable or Unwilling to Provide Informed Consent Includes individuals with cognitive impairment who lack a legally authorized representative willing to consent on their behalf.\n3. Inability to Participate in Long-Term Digital Follow-Up\n4. Concurrent Participation in an Interventional Clinical Trial Affecting Outcomes\n5. History of Malignancy Diagnosed Within the Past 12 Months\n6. Excludes patients with active or recently treated cancer unless their treating physician determines participation poses no additional safety concerns.\n7. Any Condition That, in the Investigator's Judgment, Would Compromise Data Quality\n8. Use of Non-Licensed or Counterfeit \"Muse-like\" Cells Ensures that registry data reflect outcomes of authentic Dezawa MuseCells® produced under licensed methods.\n9. Pregnant or Actively Breastfeeding at Time of Enrollment","89 Years",{"count":90,"type":21},5000,"5 Years","OBSERVATIONAL","The goal of this observational study is to learn about the long-term effects of Dezawa MuseCells to treat various diseases.\n\nThe Primary Goal: What is the short-term and long- term outcomes of Dezawa Musecells? Participants treated with Dezawa MuseCells as part of their regular medical care and will answer online survey questions about symptoms and clinical outcomes for 5 years.",[95,96,32,97,98],"Osteoarthritis (OA)","Longevity","Pain","Orthopaedic",[100,101,102,103,104],"Muse Cells","stem cells","pain","wound","inflammation","RECRUITING","2026-06-11",{"date":108,"type":45},"2026-06-12",{"date":110,"type":21},"2026-07-01",{"date":112,"type":21},"2031-12-31",{"name":114,"class":81},"MuseCell Innovations Pte LTD",2,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":125,"conditions":126,"keywords":130,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":147,"locationsCount":149},"100638268","ai-based-wound-monitoring-automated-wound-progression-assessment-via-marker-free-image-sequence-100638268","NCT07619430","AI-Based Wound Monitoring: Automated Wound Progression Assessment Via Marker-Free Image Sequence","Inclusion Criteria:\n\n* (1) Presence of a hard-to-heal wound that has remained unhealed for more than one month. (2)The wound can be photographed according to the standardized imaging protocol. (3)The participant was aged 18 years or older and provided informed consent personally or via a legally authorized representative, with a signed informed consent form.\n\nExclusion Criteria:\n\n* Wounds whose margins could not be fully included within the imaging field.","18 Years",{"count":124,"type":21},1000,"This study aims to develop a low-cost, marker-free intelligent wound assessment system that can analyze wound photos taken with a standard smartphone. By comparing wound images over time, the system will generate a quantifiable Wound Progression Index (WPI) to provide objective feedback on whether a wound is improving, stable, or worsening. The long-term goal is to support early detection of wound deterioration and improve wound care in both clinical and home settings.",[127,128,32,129],"Hard-to-heal Wounds","AI (Artificial Intelligence)","Pressure Injuries",[131,132,133,134,135,136,137,138,139,140],"chronic wounds","wound assessment","medical AI","semantic segmentation","longitudinal image registration","marker-free","wound progression index","home-based care","telemedicine","clinical validation","2026-05-27",{"date":143,"type":45},"2026-06-02",{"date":145,"type":21},"2026-06-08",{"date":49,"type":21},{"name":148,"class":52},"National Taiwan University Hospital",1,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":149},"100636175","using-woundpilot-to-support-wound-care-decisions-in-patients-with-chronic-wounds-100636175","NCT07562269","Using WoundPilot to Support Wound Care Decisions in Patients With Chronic Wounds","Evaluation of the Effect of WoundPilot on the Accuracy and Consistency of Clinical Decision-Making in Chronic Wound Care: A Randomized Parallel Vignette Study Among Primary Care Nurses","Inclusion Criteria:\n\n* Primary care nurses involved in wound care decision-making\n* Nurses working in home care or nursing home settings\n* Nurses who assess and\u002For adapt wound management in clinical practice\n* Nurses with a qualification corresponding to European Qualification Framework (EQF) level 5 or 6\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Nurses not involved in wound care decision-making\n* Nurses not working in a primary care setting\n* Inability to understand the study procedures or complete the assessment tasks\n* Refusal or inability to provide informed consent",true,{"count":159,"type":21},40,[24],"This study evaluates whether a digital decision support tool, called WoundPilot, can help primary care nurses make more accurate and consistent decisions when caring for patients with chronic wounds.\n\nIn daily practice, treatment decisions for chronic wounds can vary between clinicians, even when they assess the same patient. This variation may lead to delays in appropriate care, inconsistent treatment choices, or unnecessary referrals. WoundPilot was developed to guide clinicians through a structured wound assessment and link this assessment to clear treatment recommendations.\n\nIn this study, primary care nurses will assess a series of clinical cases either with or without the support of WoundPilot. Their decisions will be compared with an expert reference standard to determine whether the use of WoundPilot improves the accuracy of decisions and reduces differences between nurses.\n\nThe results of this study will help determine whether WoundPilot can support more consistent and evidence-based wound care in clinical practice.",[163,32,164],"Wound Complication","Wound and Injuries",[166,38,167,168,169,170,171,172,173,174],"chronic wound","clinical decision-making","decision support system","WoundPilot","Primary Care Nursing","Wound Assessment","decision-making","clinical reasoning","hard-to-heal wound","2026-04-24",{"date":177,"type":45},"2026-05-01",{"date":179,"type":21},"2026-06-01",{"date":181,"type":21},"2026-09",{"name":183,"class":52},"University Ghent",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":191,"targetDuration":192,"studyType":92,"phases":4,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":199,"leadSponsor":201,"locationsCount":4},"100635515","plasma-therapy-for-diverse-wounds-100635515","NCT07553689","Plasma Therapy for Diverse Wounds","A Prospective, Multicenter, Real-World Observational Study of a Plasma Device for Adjunctive Therapy in Acute Wounds, Chronic Wounds, Post-Grafting Wounds, and Sutured Wounds","Inclusion Criteria:\n\n* Presence of any of the following wound types: acute wounds (burns, trauma, surgical incisions, skin avulsions), chronic wounds (diabetic foot ulcers, pressure injuries, venous ulcers, radiation ulcers, burn residual wounds), post-grafting wounds (autograft or allograft, including donor and recipient sites), or sutured wounds (postoperative incisions, flap surgery, tension-reducing sutures).\n* Age ≥ 12 years (for minors under 18 years, informed consent must be provided by a parent or legal guardian).\n* Stable vital signs and able to tolerate wound treatment.\n* Willing to participate and able to provide signed informed consent.\n\nExclusion Criteria:\n\n* Active malignant tumor involving the wound area.\n* Severe systemic infection or sepsis.\n* Severe immunodeficiency or long-term use of high-dose corticosteroids.\n* Intolerance to plasma therapy or refusal to participate.\n* Pregnancy or breastfeeding.",{"count":124,"type":21},"6 Months","This study is a prospective, multicenter, real-world observational study. It aims to evaluate whether adding plasma device therapy to standard wound care is effective and safe for treating different types of wounds, including acute wounds (such as burns and surgical incisions), chronic wounds (such as diabetic foot ulcers and pressure injuries), post-grafting wounds, and sutured wounds.\n\nA total of 500 patients receiving standard wound care plus plasma therapy will be enrolled from multiple hospitals across China. Their outcomes will be compared with 500 matched patients who received standard wound care alone. The main outcomes include wound healing rate at 4 weeks, time to complete wound closure, pain relief, scar formation, and any side effects. Patients will be followed for up to 6 months.",[32],"2026-04-23",{"date":197,"type":45},"2026-04-28",{"date":177,"type":21},{"date":200,"type":21},"2029-12-31",{"name":202,"class":52},"First Affiliated Hospital, Sun Yat-Sen University",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":213,"conditions":214,"keywords":216,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":115},"100627376","the-pain-reduction-using-immersive-virtual-reality-during-wound-care-evaluation-study-at-maimonides-prism---pilot-study-100627376","NCT07447830","The Pain Reduction Using Immersive Virtual Reality During Wound Care Evaluation Study at Maimonides (PRISM) - Pilot Study","PRISM","Inclusion Criteria:\n\n* Resident of LTC for ≥2 weeks\n* Receiving regular wound care for pressure ulcers\n* Able to tolerate iVR headset use\n* (If cognitively apt) able to understand English or French\n\nExclusion Criteria:\n\n* Blindness, severe cataracts, or glaucoma\n* Allergies to synthetic plastics or headset materials\n* Head or ear wounds preventing headset placement\n* Peripheral neuropathy\n* Dangerous or aggressive behaviors in the past 30 days",{"count":211,"type":21},25,[24],"This study will test whether immersive virtual reality (iVR) can reduce pain and discomfort during wound care for residents living in long-term care (LTC). Pressure ulcers are common and painful among older adults, and dressing changes often cause additional distress.\n\nUp to 20 residents at the Donald Berman Maimonides Geriatric Centre will use virtual reality headsets during routine wound care. The headsets display calm, low-stimulus scenes (e.g., puppies in a meadow) designed to distract and comfort participants.\n\nEach participant will take part for six weeks in three phases:\n\n* Two weeks of usual wound care (baseline)\n* Two weeks using virtual reality during wound care (intervention)\n* Two weeks of usual care again (washout)\n\nPain will be assessed using validated tools, and the research team will also observe agitation, mood, and other behavioral indicators. Nursing staff will provide feedback on feasibility and acceptability of iVR use in LTC settings.",[32,97,215],"Neuropsychiatric Symptoms",[217,102,38,218,219],"immersive virtual reality","depression","aggitation","2026-03-03",{"date":222,"type":45},"2026-03-05",{"date":224,"type":45},"2025-11-01",{"date":226,"type":21},"2027-04-15",{"name":228,"class":52},"McGill University",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":235,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100619812","a-pac-post-market-clinical-study-to-demonstrate-color-change-in-the-woundcue-kit-when-an-elevated-inhibitory-bacterial-andor-fungal-load-is-present-in-a-wound-100619812","NCT07349485","A PAC Post-Market Clinical Study to Demonstrate Color Change in the WoundCue™ Kit When an Elevated Inhibitory Bacterial and\u002For Fungal Load is Present in a Wound","Inclusion Criteria:\n\n* Arm 1:\n\nSubjects will be considered qualified for enrollment if they meet the following criteria:\n\nSubjects and\u002For Legally Authorized Representative (LAR) must voluntarily provide written Informed Consent, consisting of reading, signing, and dating the Informed Consent document after the Principal Investigator, sub-Principal Investigator, or other designated Study Staff member has explained the Study procedures, risks, and contact information.\n\nAble and willing to comply with all Study requirements.\n\nSubject can be Male or Female but must be over 21 years of age.\n\nSubject is currently under the care of a Primary Care Physician.\n\nSubject has an anticipated survival of greater than two months.\n\nSubject has a moderate to high exudate wound that has visible fluorescence when using MolecuLightDX™ or MolecuLight i:X™ imaging.\n\nArm 2:\n\nSubjects will be considered qualified for enrollment if they meet the following criteria:\n\nSubjects and\u002For Legally Authorized Representative (LAR) must voluntarily provide written Informed Consent, consisting of reading, signing, and dating the Informed Consent document after the Principal Investigator, sub-Investigator, or other designated Study Staff member has explained the Study procedures, risks, and contact information.\n\nAble and willing to comply with all Study requirements.\n\nSubject can be Male or Female but must be over 21 years of age.\n\nSubject is currently under the care of a Primary Care Physician.\n\nSubject has an anticipated survival of greater than two months.\n\nSubject has a moderate to high exudate wound.\n\n\\*For this Study, moderate exudate is defined as a wound that may require a dressing change 2-3 times a week based on provider judgement. Heavy exudate is defined as a wound that may require a dressing change 4 or more times a week based on provider judgement.\n\nExclusion Criteria:\n\n* Subject's target treatment area has a surface area larger than 5 cm2.\n\nKnown sensitivity or allergy to the Study Device or adhesives\u002Fadhesive-related products.\n\nCurrent use of topical ointments, including over-the-counter products and prescription drugs, on or near the intended treatment area.\n\nCurrent use or recent history (within the past 14 days) of antibiotics, either oral, systemic, or topical.\n\nUndergoing therapy with another investigational agent that may affect the WoundCueTM Kit's performance within thirty (30) days of Study Visit 1 or planned participation overlapping with this Study.\n\nWomen who are pregnant, breastfeeding, or intend to become pregnant during the course of the Study.\n\nMedical condition that, in the opinion of the Principal Investigator, would preclude safe Subject participation in the Study.\n\nAdults who, in the judgment of the Investigator, lack the capacity to provide informed consent for themselves","21 Years",{"count":237,"type":21},50,[24],"The purpose of this research is to test if the investigational ParaNano WoundCue Kit can detect elevated inhibitory bacterial and\u002For fungal loads.",[32],"2026-01-27",{"date":243,"type":45},"2026-01-29",{"date":245,"type":21},"2026-01-21",{"date":247,"type":21},"2027-11-20",{"name":249,"class":81},"ParaNano, Inc.",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":16,"minAge":122,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":258,"briefSummary":259,"conditions":260,"keywords":264,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":4},"100589995","the-effect-of-wound-care-education-using-the-jigsaw-iv-learning-technique-on-nursing-students-knowledge-collaborative-learning-and-academic-motivation-100589995","NCT06961656","The Effect of Wound Care Education Using the Jigsaw IV Learning Technique on Nursing Students' Knowledge, Collaborative Learning, and Academic Motivation","Inclusion Criteria:\n\n* Not having taken a wound care education before\n* Willing to participate in the study voluntarily\n\nExclusion Criteria:\n\n* Being a nurse who graduated from secondary school and working in the clinic,\n* Having previously established an associate degree program related to health,\n* Not participating in theoretical lessons, demonstrations and group work, - The student wants to withdraw from the research at any stage,\n* Not filling out the data collection forms or filling them incompletely.",{"count":257,"type":21},100,[24],"This study aims to investigate the effects of wound care education given with the jigsaw IV learning technique on the knowledge, collaborative learning and motivation levels of nursing students. Second-year nursing students will be divided into two groups with simple randomization. The intervention group will be given a wound care training program with the jigsaw IV technique. The control group will be given wound care training with traditional education. Pre-test data will be collected before the training and post-test data will be collected after the training.",[261,262,263,32],"Nursing Students","Nursing Education","Jigsaw Technique",[265,266,267,268,269],"Jigsaw IV","Nursing students","Wound care","Collaboration","Motivation","2025-05-06",{"date":272,"type":45},"2025-05-08",{"date":274,"type":21},"2025-04-28",{"date":276,"type":21},"2025-05-01",{"name":278,"class":52},"Agri Ibrahim Cecen University"]